BMS’ Opdivo misses target in aggressive brain cancer trialIt’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Share XBMS’ Opdivo misses target in aggressive brain cancer trialhttps://pharmaphorum.com/news/bms-opdivo-off-target-in-aggressive-brain-cancer/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Amgen stumps up $13.4bn to claim Otezla from CelgeneCelgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen Share XAmgen stumps up $13.4bn to claim Otezla from Celgenehttps://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/
Celgene scores regulatory win ahead of BMS mergerCelgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA Share XCelgene scores regulatory win ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-scores-regulatory-win-ahead-of-bms-merger/
2nd RNA Targeted Drug Discovery SummitAt a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Share X2nd RNA Targeted Drug Discovery Summithttps://pharmaphorum.com/events/2nd-rna-targeted-drug-discovery-summit/
BMS shares fall on mixed cancer immunotherapy resultsBristol-Myers Squibb’s shares have fallen sharply in pre-opening trading after mixed results from its cancer immunotherapy Opdivo in Share XBMS shares fall on mixed cancer immunotherapy resultshttps://pharmaphorum.com/news/bms-shares-fall-on-mixed-cancer-immunotherapy-results/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Merck & Co notches up another lung cancer use for KeytrudaBristol-Myers Squibb’s immunotherapy Opdivo has new competition in small cell lung cancer (SCLC) after the FDA approved its Share XMerck & Co notches up another lung cancer use for Keytrudahttps://pharmaphorum.com/news/merck-co-notches-up-another-lung-cancer-use-for-keytruda/
Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
